Session: Poster Session B Abstract title:Combination immunotherapy with an albumin-binding interleukin-12 fusion protein that extends cytokine half-life, targets the tumor microenvironment, and ...
Holdings announced its plans to advance the development of its proprietary Antibody Drug Conjugate (ADC) platform ...
Sonnet’s exit from the Alberta auto market has allowed the online insurer to generate a profitable underwriting performance ...
PRINCETON - Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage biotechnology company specializing in immunotherapy treatments with a current market capitalization of $4.69 million, ...
Completion of SON-1010 (IL12-FHAB) monotherapy dose escalation in Phase 1 SB101 trial; Stable disease (SD) at four months post-initiation of dosing was seen in 48% evaluable monotherapy patients, and ...
Love is 'an ever-fixèd mark.' Kate Moncrief and Brendon Fox - No impediments to this marriage of true minds, true love ...
Elon Musk announced Grok 2 will soon be upgraded to Grok 3, enhancing AI interpretation on the platform. The new model, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback